|
1）Scaffidi AK, Mutsaers SE, Moodley YP, et al. Oncostatin M stimulates proliferation, induces collagen production and inhibits apoptosis of human lung fibroblasts. Br J Pharmacol. 2002; 136: 793-801
|
|
|
|
2）Mozaffarian A, Brewer AW, Trueblood ES, et al. Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J Immunol. 2008; 181: 7243-53
|
|
|
|
|
|
3）Shitrit D, Jawad AQ, Salomon P, et al. Oncostatin M in bronchoalveolar lavage correlates with the severity of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013; 30: 194-200
|
|
|
|
|
|
4）Simpson JL, Baines KJ, Boyle MJ, et al. Oncostatin M (OSM) is increased in asthma with incompletely reversible airflow obstruction. Exp Lung Res. 2009; 35: 781-94
|
|
|
|
|
|
5）Baines KJ, Simpson JL, Gibson PG. Innate immune responses are increased in chronic obstructive pulmonary disease. PLoS One. 2011; 6: e18426
|
|
|
|
|
|
6）Christ M, McCartney-Francis NL, Kulkarni AB, et al. Immune dysregulation in TGF-beta 1-deficient mice. J Immunol. 1994; 153: 1936-46
|
|
|
|
|
|
7）Lee CG, Cho S, Homer RJ, et al. Genetic control of transforming growth factor-beta1-induced emphysema and fibrosis in the murine lung. Proc Am Thorac Soc. 2006; 3: 476-77
|
|
|
|
|
|
8）Takizawa H, Tanaka M, Takami K, et al. Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med. 2001; 163: 1476-83
|
|
|
|
|
|
9）Togo S, Holz O, Liu X, et al. Lung fibroblast repair functions in patients with chronic obstructive pulmonary disease are altered by multiple mechanisms. Am J Respir Crit Care Med. 2008; 178: 248-60
|
|
|
|
|
|
10）Morris DG, Huang X, Kaminski N, et al. Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes Mmp12-dependent emphysema. Nature. 2003; 422:169-73
|
|
|
|
|
|
11）Bonniaud P, Kolb M, Galt T, et al. Smad3 null mice develop airspace enlargement and are resistant to TGF-beta-mediated pulmonary fibrosis. J Immunol. 2004; 173: 2099-108
|
|
|
|
|
|
12）Cohen M, Marchand-Adam S, Lecon-Malas V, et al. HGF synthesis in human lung fibroblasts is regulated by oncostatin M. Am J Physiol Lung Cell Mol Physiol. 2006; 290: L1097-103
|
|
|
|
|
|
13）Pechkovsky DV, Prêle CM, Wong J, et al. STAT3-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP/IPF. Am J Pathol. 2012; 180: 1398-412
|
|
|
|
|
|
14）Wong S, Botelho FM, Rodrigues RM, et al. Oncostatin M overexpression induces matrix deposition, STAT3 activation, and SMAD1 Dysregulation in lungs of fibrosis-resistant BALB/c mice. Lab Invest. 2014; 94: 1003-16
|
|
|
|
|
|
15）Langdon C, Kerr C, Tong L, et al. Oncostatin M regulates eotaxin expression in fibroblasts and eosinophilic inflammation in C57BL/6 mice. J Immunol. 2003; 170: 548-55
|
|
|
|
|
|
16）Fritz DK, Kerr C, Tong L, et al. Oncostatin-M up-regulates VCAM-1 and synergizes with IL-4 in eotaxin expression: involvement of STAT6. J Immunol. 2006; 176: 4352-60
|
|
|
|
|
|
17）Faffe DS, Flynt L, Mellema M, et al. Oncostatin M causes VEGF release from human airway smooth muscle: synergy with IL-1beta. Am J Physiol Lung Cell Mol Physiol. 2005; 288: L1040-8
|
|
|
|
|
|
18）Faffe DS, Flynt L, Mellema M, et al. Oncostatin M causes eotaxin-1 release from airway smooth muscle: synergy with IL-4 and IL-13. J Allergy Clin Immunol. 2005; 115: 514-20
|
|
|
|
|
|
19）Fritz DK, Kerr C, Botelho F, et al. Oncostatin M (OSM) primes IL-13- and IL-4-induced eotaxin responses in fibroblasts: regulation of the type-II IL-4 receptor chains IL-4Ralpha and IL-13Ralpha1. Exp Cell Res. 2009; 315: 3486-99
|
|
|
|
|
|
20）Nagahama KY, Togo S, Holz O, et al. Oncostatin M modulates fibroblast function via signal transducers and activators of transcription proteins-3. Am J Respir Cell Mol Biol. 2013; 49: 582-91
|
|
|
|
|
|
21）Tong L, Smyth D, Kerr C, et al. Mitogen-activated protein kinases Erk1/2 and p38 are required for maximal regulation of TIMP-1 by oncostatin M in murine fibroblasts. Cell Signal. 2004; 16: 1123-32
|
|
|
|
|